×
About 303 results

ALLMedicine™ Intermediate Uveitis Center

Research & Reviews  111 results

Ocular Point-of-Care Ultrasound: Description of Intermediate Uveitis in an Adolescent F...
https://doi.org/10.1097/PEC.0000000000002353
Pediatric Emergency Care; Shah R, Rychwalski P et. al.

Jun 28th, 2021 - Ocular point-of-care ultrasound has been used to assess for intraocular pathology, including retinal and vitreous detachment. We describe a pediatric patient whose initial point-of-care ultrasound examination appeared to be consistent with bilater...

The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year exper...
https://doi.org/10.1007/s10792-021-01886-y 10.1016/j.ijid.2019.07.004 10.1111/resp.13303 10.1007/BF00130924 10.1016/j.ajo.2009.11.020 10.1016/j.ophtha.2010.08.011 10.1080/09273948.2017.1296580 10.3109/09273948.2014.967358 10.1016/j.ajo.2005.03.057 10.1016/S0161-6420(85)34001-0 10.1111/j.1442-9071.1991.tb00663.x 10.1080/09273948.2018.1489061 10.1097/APO.0b013e3182950d58 10.1007/s10792-017-0716-y 10.1001/jamaophthalmol.2017.4485 10.1016/j.survophthal.2016.03.001 10.1080/09273948.2018.1484496 10.1097/01.iio.0000155935.60213.ac 10.1001/archopht.1976.03910030482009 10.1186/1869-5760-3-11 10.3109/09273948.2012.658134 10.1007/s10792-015-0144-9 10.1097/IAE.0000000000001239 10.1097/IAE.0000000000002194 10.3109/09273948.2011.594203 10.3109/09273948.2014.986582 10.1080/092739490500354 10.1001/archopht.1997.01100150432025 10.1016/S0161-6420(01)00693-5 10.2147/OPTH.S65254 10.1016/j.ajo.2008.06.011 10.1136/bjophthalmol-2011-300209 10.3109/09273948.2014.986584 10.1016/S0161-6420(02)00973-9 10.1038/eye.2010.110 10.1038/s41433-018-0224-y 10.1007/s12348-011-0020-3 10.3928/01913913-20080701-15 10.1167/iovs.18-24102 10.1210/jcem-59-6-1204 10.1034/j.1600-0420.1998.760609.x 10.1080/09273948.2017.1400074 10.1016/j.ijid.2008.09.018 10.1097/00055735-200012000-00010 10.1148/rg.2017160032
International Ophthalmology; Tsui J, Ho M et. al.

May 26th, 2021 - To report the clinical presentations of ocular tuberculosis infection (OTB) and the treatment regimen and outcome in an endemic area. This is a retrospective case series of patients with presumed OTB treated in a tertiary teaching hospital in Hong...

Classification criteria for pars planitis.
https://doi.org/10.1016/j.ajo.2021.03.045
American Journal of Ophthalmology; The Standardization Of Uveitis Nomenclature Sun Working Group , Jabs DA et. al.

Apr 12th, 2021 - To determine classification criteria for pars planitis DESIGN: Machine learning of cases with pars planitis and 4 other intermediate uveitides. Cases of intermediate uveitides were collected in an informatics-designed preliminary database, and a f...

Classification Criteria for Multiple Sclerosis-Associated Intermediate Uveitis.
https://doi.org/10.1016/j.ajo.2021.03.044
American Journal of Ophthalmology;

Apr 12th, 2021 - The purpose of this study was to determine classification criteria for multiple sclerosis-associated intermediate uveitis. Machine learning of cases with multiple sclerosis-associated intermediate uveitis and 4 other intermediate uveitides. Cases ...

Classification Criteria for Intermediate Uveitis, Non-Pars Planitis Type.
https://doi.org/10.1016/j.ajo.2021.03.054
American Journal of Ophthalmology;

Apr 11th, 2021 - To determine classification criteria for intermediate uveitis, non-pars planitis type (IU-NPP, also known as undifferentiated intermediate uveitis). Machine learning of cases with IU-NPP and 4 other intermediate uveitides. Cases of intermediate uv...

see more →

Clinicaltrials.gov  5 results

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate
https://clinicaltrials.gov/ct2/show/NCT01314417

Mar 26th, 2019 - OBJECTIVE: The study objective is to investigate the safety, tolerability and potential efficacy of intravitreal injections of methotrexate as a possible treatment for chronic macular edema secondary to panuveitis, posterior or intermediate uveiti...

Multicenter Uveitis Steroid Treatment (MUST) Trial
https://clinicaltrials.gov/ct2/show/NCT00132691

Nov 24th, 2016 - The MUST trial is a randomized controlled clinical trial comparing two treatments for patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or panuveitis: local therapy with fluocinolone acetonide intraocular imp...

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
https://clinicaltrials.gov/ct2/show/NCT01124838

Aug 10th, 2016 - A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

Quality of Life in Patients With Intermediate Uveitis
https://clinicaltrials.gov/ct2/show/NCT01314469

Jul 20th, 2011 - The aim of this study is to determine if macular edema is associated with less visual function and quality of live in patients with intermediate uveitis

Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
https://clinicaltrials.gov/ct2/show/NCT00043667

Mar 3rd, 2008 - Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects. Consequently, an effective treatment with a safer si...

see more →

News  4 results

FDA Clears Adalimumab (Humira) for Uveitis
https://www.medscape.com/viewarticle/865654

Jun 30th, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.staging.medscape.com/viewarticle/865654

Jun 30th, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Grants Orphan Drug Status to Gevokizumab
https://www.medscape.com/viewarticle/769952

Aug 28th, 2012 - August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL-1β), for the treatment of noninfectious intermediate u...

Systemic diseases associated with intermediate uveitis
https://www.mdedge.com/ccjm/article/92786/systemic-diseases-associated-intermediate-uveitis

Abstract BACKGROUND Intermediate uveitis is characterized by vitreal inflammation with associated inflammation of the vitreous base and peripheral anterior retina and choroid. It may be found as an isolated and idiopathic condition or in associati.

see more →

Patient Education  1 results see all →